247 related articles for article (PubMed ID: 21678117)
21. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of autophagy as a strategy to augment radiosensitization by the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
Cerniglia GJ; Karar J; Tyagi S; Christofidou-Solomidou M; Rengan R; Koumenis C; Maity A
Mol Pharmacol; 2012 Dec; 82(6):1230-40. PubMed ID: 22989521
[TBL] [Abstract][Full Text] [Related]
23. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
[TBL] [Abstract][Full Text] [Related]
24. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.
Wallin JJ; Edgar KA; Guan J; Berry M; Prior WW; Lee L; Lesnick JD; Lewis C; Nonomiya J; Pang J; Salphati L; Olivero AG; Sutherlin DP; O'Brien C; Spoerke JM; Patel S; Lensun L; Kassees R; Ross L; Lackner MR; Sampath D; Belvin M; Friedman LS
Mol Cancer Ther; 2011 Dec; 10(12):2426-36. PubMed ID: 21998291
[TBL] [Abstract][Full Text] [Related]
25. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
[TBL] [Abstract][Full Text] [Related]
26. Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models.
Zhong H; Sanchez C; Spitzer D; Plambeck-Suess S; Gibbs J; Hawkins WG; Denardo D; Gao F; Pufahl RA; Lockhart AC; Xu M; Linehan D; Weber J; Wang-Gillam A
PLoS One; 2013; 8(10):e77243. PubMed ID: 24130864
[TBL] [Abstract][Full Text] [Related]
27. Efemp1 and p27(Kip1) modulate responsiveness of pancreatic cancer cells towards a dual PI3K/mTOR inhibitor in preclinical models.
Diersch S; Wenzel P; Szameitat M; Eser P; Paul MC; Seidler B; Eser S; Messer M; Reichert M; Pagel P; Esposito I; Schmid RM; Saur D; Schneider G
Oncotarget; 2013 Feb; 4(2):277-88. PubMed ID: 23470560
[TBL] [Abstract][Full Text] [Related]
28. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
Guenther MK; Graab U; Fulda S
Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
[TBL] [Abstract][Full Text] [Related]
29. Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer.
Cardnell RJ; Feng Y; Mukherjee S; Diao L; Tong P; Stewart CA; Masrorpour F; Fan Y; Nilsson M; Shen Y; Heymach JV; Wang J; Byers LA
PLoS One; 2016; 11(4):e0152584. PubMed ID: 27055253
[TBL] [Abstract][Full Text] [Related]
30. Piperlongumine induces apoptosis and autophagy in human lung cancer cells through inhibition of PI3K/Akt/mTOR pathway.
Wang F; Mao Y; You Q; Hua D; Cai D
Int J Immunopathol Pharmacol; 2015 Sep; 28(3):362-73. PubMed ID: 26246196
[TBL] [Abstract][Full Text] [Related]
31. Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells.
Zito CR; Jilaveanu LB; Anagnostou V; Rimm D; Bepler G; Maira SM; Hackl W; Camp R; Kluger HM; Chao HH
PLoS One; 2012; 7(2):e31331. PubMed ID: 22355357
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K/mTOR inhibitors.
Echeverry N; Ziltener G; Barbone D; Weder W; Stahel RA; Broaddus VC; Felley-Bosco E
Cell Death Dis; 2015 May; 6(5):e1757. PubMed ID: 25950487
[TBL] [Abstract][Full Text] [Related]
33. Licochalcone A induces autophagy through PI3K/Akt/mTOR inactivation and autophagy suppression enhances Licochalcone A-induced apoptosis of human cervical cancer cells.
Tsai JP; Lee CH; Ying TH; Lin CL; Lin CL; Hsueh JT; Hsieh YH
Oncotarget; 2015 Oct; 6(30):28851-66. PubMed ID: 26311737
[TBL] [Abstract][Full Text] [Related]
34. Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor.
Zou CY; Smith KD; Zhu QS; Liu J; McCutcheon IE; Slopis JM; Meric-Bernstam F; Peng Z; Bornmann WG; Mills GB; Lazar AJ; Pollock RE; Lev D
Mol Cancer Ther; 2009 May; 8(5):1157-68. PubMed ID: 19417153
[TBL] [Abstract][Full Text] [Related]
35. Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer.
Beale G; Haagensen EJ; Thomas HD; Wang LZ; Revill CH; Payne SL; Golding BT; Hardcastle IR; Newell DR; Griffin RJ; Cano C
Br J Cancer; 2016 Sep; 115(6):682-90. PubMed ID: 27529512
[TBL] [Abstract][Full Text] [Related]
36. JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice.
Song X; Zhu S; Xie Y; Liu J; Sun L; Zeng D; Wang P; Ma X; Kroemer G; Bartlett DL; Billiar TR; Lotze MT; Zeh HJ; Kang R; Tang D
Gastroenterology; 2018 Apr; 154(5):1480-1493. PubMed ID: 29248440
[TBL] [Abstract][Full Text] [Related]
37. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
Shoji K; Oda K; Kashiyama T; Ikeda Y; Nakagawa S; Sone K; Miyamoto Y; Hiraike H; Tanikawa M; Miyasaka A; Koso T; Matsumoto Y; Wada-Hiraike O; Kawana K; Kuramoto H; McCormick F; Aburatani H; Yano T; Kozuma S; Taketani Y
PLoS One; 2012; 7(5):e37431. PubMed ID: 22662154
[TBL] [Abstract][Full Text] [Related]
38. A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate.
Falasca M; Chiozzotto D; Godage HY; Mazzoletti M; Riley AM; Previdi S; Potter BV; Broggini M; Maffucci T
Br J Cancer; 2010 Jan; 102(1):104-14. PubMed ID: 20051961
[TBL] [Abstract][Full Text] [Related]
39. Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy.
Chang Z; Shi G; Jin J; Guo H; Guo X; Luo F; Song Y; Jia X
Int J Mol Med; 2013 Jun; 31(6):1449-56. PubMed ID: 23588698
[TBL] [Abstract][Full Text] [Related]
40. PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.
Yuan J; Mehta PP; Yin MJ; Sun S; Zou A; Chen J; Rafidi K; Feng Z; Nickel J; Engebretsen J; Hallin J; Blasina A; Zhang E; Nguyen L; Sun M; Vogt PK; McHarg A; Cheng H; Christensen JG; Kan JL; Bagrodia S
Mol Cancer Ther; 2011 Nov; 10(11):2189-99. PubMed ID: 21750219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
